Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42096521.
- Also identified by DOI 10.1126/science.aec6396.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A major obstacle confronting HIV-1 vaccine and cure research is the lack of an outbred animal model for rapid and consistent induction of broadly neutralizing antibodies (bNAbs). We designed an epitope-focused simian-human immunodeficiency virus (SHIV.5MUT) that elicited broad and potent V3-glycan-targeted antibodies within a year of infection in 14 of 22 macaques compared with 0 of 14 control animals. SHIV.5MUT elicited bNAbs by a two-step mechanism, inducing an initial wave of V1-directed antibodies that selected for envelope (Env) glycoprotein variants with shortened, hypoglycosylated V1 loops, which in turn primed V3-glycan bNAb precursors. Rhesus bNAbs were immunogenetically and structurally diverse, closely resembling human V3-glycan bNAbs. Env-bNAb coevolution revealed a diverse repertoire of bNAb precursors and the Env variants that matured them, yielding a molecular blueprint for vaccine design.
Medical subject headings
- AIDS Vaccines
- Broadly Neutralizing Antibodies
- env Gene Products, Human Immunodeficiency Virus
- HIV Antibodies
- HIV Infections
- HIV-1
- Simian Immunodeficiency Virus
- Vaccine Development